Absci to Participate in the 25th Annual Needham Virtual Healthcare Conference

Absci to Present at 25th Annual Needham Virtual Healthcare Conference Showcasing AI-driven Drug Discovery Innovations

By Marcus Reed ABSI

Absci to Participate in the 25th Annual Needham Virtual Healthcare Conference

ABSI

Absci Corporation, a clinical-stage biopharmaceutical company specializing in AI-driven drug discovery, announced its participation in the 25th Annual Needham Virtual Healthcare Conference. The company will engage in a fireside chat highlighting its Integrated Drug Creation platform and promising pipeline assets like ABS-201, focused on hair regrowth and endometriosis treatments with significant market potential.

Key Points

Absci leverages generative AI combined with synthetic biology for rapid, innovative biologics design, improving drug discovery precision and speed.
The company’s proprietary Integrated Drug Creation platform enables continuous feedback between AI models and lab validation, enhancing therapeutic innovation.
ABS-201, Absci's lead therapeutic candidate, targets androgenetic alopecia and endometriosis, both with significant unmet medical needs and commercial opportunities.

VANCOUVER, Wash. and NEW YORK, April 08, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today announced the company will be participating in the upcoming 25th Annual Needham Virtual Healthcare Conference.

Absci management is scheduled to participate in a fireside chat on Thursday, April 16th at 1:30 p.m. Eastern Time (10:30 a.m. Pacific Time). Interested parties may access a live and archived webcast on the company’s investor relations website at: investors.absci.com.

About Absci

Absci is advancing the future of drug discovery with generative design to create better biologics for patients, faster. Our Integrated Drug Creation™ platform combines cutting-edge AI models with a synthetic biology data engine, enabling the rapid design of innovative therapeutics that address challenging therapeutic targets. Absci’s approach leverages a continuous feedback loop between advanced AI algorithms and wet lab validation. Each cycle refines our data and strengthens our models, facilitating rapid innovation and enhancing the precision of our therapeutic designs. Alongside collaborations with top pharmaceutical, biotech, tech, and academic leaders, Absci is advancing its own pipeline of AI designed therapeutics including ABS-201™, a groundbreaking innovation in hair regrowth with the potential to redefine treatment possibilities for androgenetic alopecia, commonly known as male and female pattern hair-loss. ABS-201 is also being investigated as a potential “best-in-class” therapeutic for endometriosis, a condition with significant unmet medical need and market potential. Absci is headquartered in Vancouver, WA, with AI Research Labs in New York City and Serbia, and an Innovation Center in Switzerland. Learn more at www.absci.com or follow us on LinkedIn (@absci), X (@Abscibio) and YouTube.

Absci® standard character mark, ABS-201™, and Integrated Drug Creation™ are trademarks and registered trademarks of Absci Corporation.

Investor Contact
Alexander D.H. Khan
Corporate Vice President
Head of Investor Relations
[email protected]

Media Contact
[email protected]

Risks

As a clinical-stage company, Absci faces regulatory approval risks related to the safety and efficacy of its pipeline therapeutics.
Dependence on the success of AI-driven drug design platforms, which are innovative but may encounter technological or development challenges.
Market competition from other biotech companies developing treatments for hair loss and endometriosis could impact Absci's commercial prospects.

Menu

Absci to Participate in the 25th Annual Needham Virtual Healthcare Conference

Key Points

Risks

More from Press Releases